Provided by Tiger Trade Technology Pte. Ltd.

Kyverna Therapeutics

8.42
+0.29003.57%
Post-market: 8.450.0320+0.38%19:30 EDT
Volume:663.61K
Turnover:5.56M
Market Cap:520.72M
PE:-2.92
High:8.58
Open:8.24
Low:8.19
Close:8.13
52wk High:13.67
52wk Low:3.50
Shares:61.84M
Float Shares:39.72M
Volume Ratio:0.77
T/O Rate:1.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.8809
EPS(LYR):-3.6445
ROE:-87.24%
ROA:-44.51%
PB:3.15
PE(LYR):-2.31

Loading ...

Company Profile

Company Name:
Kyverna Therapeutics
Exchange:
NASDAQ
Establishment Date:
2018
Employees:
149
Office Location:
5980 Horton Street,Suite 550,EmeryVille,California,United States
Zip Code:
94608
Fax:
- -
Introduction:
Kyverna Therapeutics, Inc. was incorporated in Delaware in June 2018 under the name BAIT Therapeutics, Inc. and renamed Kyverna Therapeutics, Inc. in October 2019. The company is a patient-centric, clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. Its goal is to deliver disease-modifying therapeutic benefits through a patient-centered approach, a broad platform, insights into treating immune diseases, and lessons learned from the successful application of cell therapy in medicine.

Directors

Name
Position
Warner Biddle
Chief Executive Officer and Director
Christi Shaw
Director and Executive Chairperson
Andrew Miller
Director
Beth Seidenberg
Director
Fred E. Cohen
Director
Ian Clark
Director
Mert Aktar
Director
Sravan Emany
Director

Shareholders

Name
Position
Warner Biddle
Chief Executive Officer and Director
Marc Grasso
Chief Financial Officer
Christi Shaw
Director and Executive Chairperson
Mayo Pujols
Chief Technology Officer
Naji H. Gehchan
Chief Medical and Development Officer